In this episode of Medsider Radio, we sat down with Shaun Bagai, CEO of RenovoRx.

The company is developing targeted oncology therapies and is currently commercializing RenovoCath, which is focused on pancreatic cancer.

Before joining RenovoRx in 2014, Shaun spent over a decade in the cardiovascular space, including leading global market development at HeartFlow and helping establish the European renal denervation market at Ardian, which Medtronic acquired for approximately $1 billion. He began his career in clinical research and device sales at TransVascular and Medtronic.

In this interview, Shaun discusses how testing markets with minimal infrastructure reveals what leads to commercial success, why clinical trial enrollment benefits from sales discipline, and what founders should understand about going public when traditional capital isn't available.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.

These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.

If you'd rather read than listen, here's a link to the full interview with Shaun Bagai.

Why Commercial Discipline Starts Long Before Launch: Interview with RenovoRx CEO Shaun Bagai

Medsider: Learn from Medtech and Healthtech Founders and CEOs

Why Commercial Discipline Starts Long Before Launch: Interview with RenovoRx CEO Shaun Bagai